MAXCYTE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 313 GBX | 0.00% |
|
-5.15% | -11.21% |
| Apr. 02 | MaxCyte inks deal with Be Bio; Orcadian firms farmout | AN |
| Apr. 02 | MaxCyte, Inc. Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines | CI |
Financials (USD)
| Sales 2024 * | 34.22M | Sales 2025 * | 45.52M | Capitalization | 406M |
|---|---|---|---|---|---|
| Net income 2024 * | -51M | Net income 2025 * | -45M | EV / Sales 2024 * | 6.8 x |
| Net cash position 2024 * | 173M | Net cash position 2025 * | 143M | EV / Sales 2025 * | 5.78 x |
| P/E ratio 2024 * |
-7.82
x | P/E ratio 2025 * |
-9.31
x | Employees | 143 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.02% |
More Fundamentals
* Assessed data
More news
Latest transcript on MaxCyte, Inc.
More recommendations
More press releases
| 1 week | -5.15% | ||
| Current month | -8.61% | ||
| 1 month | -4.43% | ||
| 3 months | -24.12% | ||
| 6 months | +27.76% | ||
| Current year | -11.21% |
1 week
310.00
330.00
1 month
310.00360.00
Current year
300.00430.00
1 year
170.00435.00
3 years
170.001 235.00
5 years
95.001 235.00
10 years
75.001 235.00
| Managers | Title | Age | Since |
|---|---|---|---|
Maher Masoud
CEO | Chief Executive Officer | 49 | - |
Douglas Swirsky
DFI | Director of Finance/CFO | 54 | 23-03-26 |
James Brady
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Patrick Balthrop
BRD | Director/Board Member | 67 | 22-11-30 |
Art Mandell
BRD | Director/Board Member | 71 | 06-04-30 |
Will Brooke
BRD | Director/Board Member | 68 | 04-02-29 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.20% | 12 M€ | -.--% | - | |
| 0.06% | 0 M€ | 0.00% | - | |
| 0.04% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 313 | 0.00% | 458 |
| 24-04-18 | 313 | -0.63% | 273 |
| 24-04-17 | 315 | 0.00% | 7,144 |
| 24-04-16 | 315 | 0.00% | 225 |
| 24-04-15 | 315 | -4.55% | 7,673 |
Delayed Quote London S.E., April 19, 2024 at 11:35 am EDT
More quotes
MaxCyte, Inc. is a commercial cell engineering company. The Company is focused on providing enabling platform technologies to advance the discovery, development and commercialization of cell therapeutics, including cell and gene therapies, and to support cell-based research and development. It has developed and commercialized its proprietary Flow Electroporation technology, which is used by biopharmaceutical companies in the complex engineering of a variety of cells. Its ExPERT platform is based on its Flow Electroporation technology, which has been designed to address this rapidly expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of cell-based medicines. The ExPERT family of products includes four instruments, which are known as the ATx, STx, GTx and VLx, as well as a portfolio of proprietary related disposables and consumables.
Calendar
2024-05-07
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
3.885
USD
Average target price
9.631
USD
Spread / Average Target
+147.87%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.21% | 407M | |
| +2.64% | 207B | |
| +1.80% | 175B | |
| +8.59% | 132B | |
| +16.47% | 99.1B | |
| -3.42% | 60.89B | |
| +12.71% | 52.04B | |
| -6.61% | 45.48B | |
| -4.53% | 38.81B | |
| +9.27% | 38.77B |
- Stock Market
- Equities
- MXCT Stock
